SLC22A11

Solute carrier family 22 member 11 · Q9NSA0 · SLC22A11 on Sugi Atlas →

45,368 patent compounds predicted against SLC22A11, 33,707 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Cefotaxime (SCHEMBL1279697)	0.68	3/20
Cefetrizole (SCHEMBL614464)	0.62	3/20
Cefotiam (SCHEMBL149538)	0.51	3/20
Cefotiam (SCHEMBL65480)	0.51	3/20
Cefotiam (SCHEMBL193845)	0.51	3/20
Cefotiam (SCHEMBL719723)	0.50	3/20
Cephalothin (SCHEMBL2990)	1.00	2/20
Cephaloridine (SCHEMBL3936)	1.00	2/20
Cefotaxime (SCHEMBL15410)	1.00	2/20
Cefotaxime (SCHEMBL15411)	1.00	2/20
Ceftriaxone (SCHEMBL23355)	1.00	2/20
Ceftriaxone (SCHEMBL23356)	1.00	2/20
Cefoperazone (SCHEMBL37056)	1.00	2/20
Cefamandole (SCHEMBL37287)	1.00	2/20
Ceftriaxone (SCHEMBL1447498)	1.00	2/20
Cefoperazone (SCHEMBL40452)	0.99	2/20
Ceftriaxone (SCHEMBL40850)	0.99	2/20
Cefotaxime (SCHEMBL41091)	0.98	2/20
Cefotaxime (SCHEMBL41093)	0.98	2/20
Cefamandole (SCHEMBL146171)	0.98	2/20

Clinical trials — most relevant to SLC22A11 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Age on the Renal Clearance of Adefovir	PHASE4	WITHDRAWN
Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation	PHASE2/PHASE3	UNKNOWN
Treatment of Ectopic Calcification in Fahr's Disease or Syndrome	PHASE2	RECRUITING
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)	PHASE2	COMPLETED
CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops	PHASE2	UNKNOWN
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery	PHASE2	COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime	PHASE1	COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer	EARLY_PHASE1	UNKNOWN
SLC13A5 Deficiency Natural History Study - United States Only	nan	ENROLLING_BY_INVITATION
SLC13A5 Deficiency Natural History Study - Remote Only	nan	ENROLLING_BY_INVITATION
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides	nan	COMPLETED
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts	nan	COMPLETED
Oxalate and Citrate in Humans - Response to Citrate	nan	RECRUITING
Cancer and Hearing Loss Related in Children	nan	COMPLETED
Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient	nan	UNKNOWN
Bile Acid Effects in Fetal Arrhythmia Study	nan	UNKNOWN
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Genetics of Hyperuricemia Therapy in Hmong	nan	COMPLETED
Understanding Methotrexate Induced Gastrointestinal Intolerance in Juvenile Idiopathic Arthritis and Childhood Leukemia	nan	COMPLETED
Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL	nan	COMPLETED
SLC6A1-NDD Prospective Longitudinal Natural History Study	nan	NOT_YET_RECRUITING
Autonomic Function in Patients With COPD	nan	COMPLETED
Impact of Genetics on Metformin Pharmacokinetics	nan	COMPLETED
Gyrate Atrophy Ocular and Systemic Study	nan	ACTIVE_NOT_RECRUITING
Effect of Pharmacogenetics on Imatinib Plasma Level and Response	nan	COMPLETED
ADPKD Alterations in Hepatic Transporter Function	nan	COMPLETED
Gastrostomy-Biliary Diversion: Innovative Management for Bile Canalicular Transport Disorders	nan	UNKNOWN
Effect of SLC01B1 (rs4149956) Polymorphism on the Efficacy and Tolerability of Atorvastatin in Pakistani Population	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC22A11 binder may also engage these)

Protein	Name	Similarity
SLC22A12	Solute carrier family 22 member 12	0.991	landscape →
Q8CFZ5	—	0.986	Q8CFZ5 →
Q2KIV1	—	0.985	Q2KIV1 →
Q3ZAV1	—	0.983	Q3ZAV1 →
A0A8B7HA97	—	0.982	A0A8B7HA97 →
Q5RCH6	—	0.975	Q5RCH6 →
Q6T423	—	0.974	Q6T423 →
Q4W8A3	—	0.972	Q4W8A3 →
Q8IVM8	—	0.970	Q8IVM8 →
Q9TSY7	—	0.970	Q9TSY7 →
SLC22A6	Solute carrier family 22 member 6	0.969	landscape →
Q63ZE4	—	0.969	Q63ZE4 →
Q8VCA0	—	0.968	Q8VCA0 →
Q864Z3	—	0.961	Q864Z3 →
A0A3Q2IDB4	—	0.958	A0A3Q2IDB4 →
Q76M99	—	0.957	Q76M99 →
Q8N4F4	—	0.956	Q8N4F4 →
Q8MK48	—	0.954	Q8MK48 →
Q5RC45	—	0.953	Q5RC45 →
G1SZD9	—	0.949	G1SZD9 →
Q8VC69	—	0.944	Q8VC69 →
Q9BYW1	—	0.944	Q9BYW1 →
Q76M72	—	0.942	Q76M72 →
O35956	—	0.941	O35956 →
Q6ZMD2	—	0.919	Q6ZMD2 →
SLC22A8	Organic anion transporter 3	0.916	landscape →
Q5R9C4	—	0.915	Q5R9C4 →
Q1RPP5	—	0.915	Q1RPP5 →
A6NKX4	—	0.913	A6NKX4 →
Q4W8A2	—	0.912	Q4W8A2 →